ID   CERT_HUMAN              Reviewed;         624 AA.
AC   Q9Y5P4; A8K7S2; B3KUB7; Q53YV1; Q53YV2; Q96Q85; Q96Q88; Q9H2S7; Q9H2S8;
DT   15-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   12-OCT-2022, entry version 193.
DE   RecName: Full=Ceramide transfer protein {ECO:0000303|PubMed:14685229, ECO:0000305};
DE            Short=hCERT {ECO:0000303|PubMed:14685229};
DE   AltName: Full=Collagen type IV alpha-3-binding protein {ECO:0000305};
DE   AltName: Full=Goodpasture antigen-binding protein {ECO:0000303|PubMed:10212244};
DE            Short=GPBP;
DE   AltName: Full=START domain-containing protein 11;
DE            Short=StARD11;
DE   AltName: Full=StAR-related lipid transfer protein 11;
GN   Name=CERT1 {ECO:0000312|HGNC:HGNC:2205};
GN   Synonyms=CERT, COL4A3BP {ECO:0000312|HGNC:HGNC:2205}, STARD11;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.
RX   PubMed=10212244; DOI=10.1074/jbc.274.18.12642;
RA   Raya A., Revert F., Navarro S., Saus J.;
RT   "Characterization of a novel type of serine/threonine kinase that
RT   specifically phosphorylates the human goodpasture antigen.";
RL   J. Biol. Chem. 274:12642-12649(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=11007769; DOI=10.1074/jbc.m002769200;
RA   Raya A., Revert-Ros F., Martinez-Martinez P., Navarro S., Rosello E.,
RA   Vieites B., Granero F., Forteza J., Saus J.;
RT   "Goodpasture antigen-binding protein, the kinase that phosphorylates the
RT   Goodpasture antigen, is an alternatively spliced variant implicated in
RT   autoimmune pathogenesis.";
RL   J. Biol. Chem. 275:40392-40399(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND DOMAIN START.
RX   PubMed=14685229; DOI=10.1038/nature02188;
RA   Hanada K., Kumagai K., Yasuda S., Miura Y., Kawano M., Fukasawa M.,
RA   Nishijima M.;
RT   "Molecular machinery for non-vesicular trafficking of ceramide.";
RL   Nature 426:803-809(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3).
RC   TISSUE=Lung, and Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-77.
RA   Ogi T., Yamamoto Y., Ohmori H.;
RT   "Homo sapiens genomic sequence, containing DINB1 and GPBP gene.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-315, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   INTERACTION WITH VAPA AND VAPB, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   ASP-324, DOMAIN FFAT MOTIF, AND DOMAIN PH.
RX   PubMed=16895911; DOI=10.1074/jbc.m605032200;
RA   Kawano M., Kumagai K., Nishijima M., Hanada K.;
RT   "Efficient trafficking of ceramide from the endoplasmic reticulum to the
RT   Golgi apparatus requires a VAMP-associated protein-interacting FFAT motif
RT   of CERT.";
RL   J. Biol. Chem. 281:30279-30288(2006).
RN   [11]
RP   PHOSPHORYLATION AT SER-132, FUNCTION, AND MUTAGENESIS OF SER-132.
RX   PubMed=17591919; DOI=10.1083/jcb.200612017;
RA   Fugmann T., Hausser A., Schoeffler P., Schmid S., Pfizenmaier K.,
RA   Olayioye M.A.;
RT   "Regulation of secretory transport by protein kinase D-mediated
RT   phosphorylation of the ceramide transfer protein.";
RL   J. Cell Biol. 178:15-22(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION BY CSNK1G2/CK1.
RX   PubMed=19005213; DOI=10.1091/mbc.e08-07-0669;
RA   Tomishige N., Kumagai K., Kusuda J., Nishijima M., Hanada K.;
RT   "Casein kinase I{gamma}2 down-regulates trafficking of ceramide in the
RT   synthesis of sphingomyelin.";
RL   Mol. Biol. Cell 20:348-357(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-126; TYR-372; SER-373 AND
RP   SER-380, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   INVOLVEMENT IN MRD34, AND VARIANT MRD34 LEU-132.
RX   PubMed=25533962; DOI=10.1038/nature14135;
RG   Deciphering Developmental Disorders Study;
RT   "Large-scale discovery of novel genetic causes of developmental
RT   disorders.";
RL   Nature 519:223-228(2015).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH MOSPD2, SUBCELLULAR
RP   LOCATION, DOMAIN, FFAT MOTIF, AND MUTAGENESIS OF ASP-324.
RX   PubMed=29858488; DOI=10.15252/embr.201745453;
RA   Di Mattia T., Wilhelm L.P., Ikhlef S., Wendling C., Spehner D., Nomine Y.,
RA   Giordano F., Mathelin C., Drin G., Tomasetto C., Alpy F.;
RT   "Identification of MOSPD2, a novel scaffold for endoplasmic reticulum
RT   membrane contact sites.";
RL   EMBO Rep. 19:0-0(2018).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 347-624 IN COMPLEXES WITH
RP   CERAMIDES AND DIACYLGLYCEROL, MUTAGENESIS OF GLU-472; GLN-493 AND ASN-530,
RP   FUNCTION, SUBCELLULAR LOCATION, AND CERAMIDE-BINDING.
RX   PubMed=18184806; DOI=10.1073/pnas.0709191105;
RA   Kudo N., Kumagai K., Tomishige N., Yamaji T., Wakatsuki S., Nishijima M.,
RA   Hanada K., Kato R.;
RT   "Structural basis for specific lipid recognition by CERT responsible for
RT   nonvesicular trafficking of ceramide.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:488-493(2008).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.66 ANGSTROMS) OF 347-624 IN COMPLEXES WITH
RP   CERAMIDE AND INHIBITOR, MUTAGENESIS OF TRP-499, FUNCTION, AND
RP   CERAMIDE-BINDING.
RX   PubMed=20036255; DOI=10.1016/j.jmb.2009.12.029;
RA   Kudo N., Kumagai K., Matsubara R., Kobayashi S., Hanada K., Wakatsuki S.,
RA   Kato R.;
RT   "Crystal structures of the CERT START domain with inhibitors provide
RT   insights into the mechanism of ceramide transfer.";
RL   J. Mol. Biol. 396:245-251(2010).
RN   [22]
RP   VARIANT CYS-138.
RX   PubMed=23033978; DOI=10.1056/nejmoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P., Gilissen C.,
RA   del Rosario M., Hoischen A., Scheffer H., de Vries B.B., Brunner H.G.,
RA   Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
RN   [23]
RP   VARIANT MRD34 ARG-243.
RX   PubMed=25356899; DOI=10.1371/journal.pgen.1004772;
RA   Hamdan F.F., Srour M., Capo-Chichi J.M., Daoud H., Nassif C., Patry L.,
RA   Massicotte C., Ambalavanan A., Spiegelman D., Diallo O., Henrion E.,
RA   Dionne-Laporte A., Fougerat A., Pshezhetsky A.V., Venkateswaran S.,
RA   Rouleau G.A., Michaud J.L.;
RT   "De novo mutations in moderate or severe intellectual disability.";
RL   PLoS Genet. 10:E1004772-E1004772(2014).
CC   -!- FUNCTION: Shelters ceramides and diacylglycerol lipids inside its START
CC       domain and mediates the intracellular trafficking of ceramides and
CC       diacylglycerol lipids in a non-vesicular manner.
CC       {ECO:0000269|PubMed:14685229, ECO:0000269|PubMed:17591919,
CC       ECO:0000269|PubMed:18184806, ECO:0000269|PubMed:20036255}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N-hexadecanoylsphing-4-enine(in) = N-hexadecanoylsphing-4-
CC         enine(out); Xref=Rhea:RHEA:45720, ChEBI:CHEBI:72959;
CC         Evidence={ECO:0000250|UniProtKB:Q6VVX2};
CC   -!- SUBUNIT: Interacts with VAPA and VAPB. Interaction with VAPB is less
CC       efficient than with VAPA (PubMed:16895911). Interacts (via FFAT motif)
CC       with MOSPD2 (via MSP domain) (PubMed:29858488).
CC       {ECO:0000269|PubMed:16895911, ECO:0000269|PubMed:29858488}.
CC   -!- INTERACTION:
CC       Q9Y5P4; Q9H568: ACTL8; NbExp=3; IntAct=EBI-739994, EBI-10306917;
CC       Q9Y5P4; Q15041: ARL6IP1; NbExp=5; IntAct=EBI-739994, EBI-714543;
CC       Q9Y5P4; P78368: CSNK1G2; NbExp=5; IntAct=EBI-739994, EBI-748380;
CC       Q9Y5P4; Q13352: ITGB3BP; NbExp=4; IntAct=EBI-739994, EBI-712105;
CC       Q9Y5P4; O95197: RTN3; NbExp=3; IntAct=EBI-739994, EBI-740467;
CC       Q9Y5P4; Q9NQC3: RTN4; NbExp=3; IntAct=EBI-739994, EBI-715945;
CC       Q9Y5P4-1; P02743: APCS; NbExp=6; IntAct=EBI-21199571, EBI-2115799;
CC       Q9Y5P4-2; Q9H568: ACTL8; NbExp=3; IntAct=EBI-11156432, EBI-10306917;
CC       Q9Y5P4-2; P02743: APCS; NbExp=4; IntAct=EBI-11156432, EBI-2115799;
CC       Q9Y5P4-2; Q15041: ARL6IP1; NbExp=3; IntAct=EBI-11156432, EBI-714543;
CC       Q9Y5P4-2; Q8WZ55: BSND; NbExp=3; IntAct=EBI-11156432, EBI-7996695;
CC       Q9Y5P4-2; Q9Y5P4-2: CERT1; NbExp=3; IntAct=EBI-11156432, EBI-11156432;
CC       Q9Y5P4-2; P78368: CSNK1G2; NbExp=4; IntAct=EBI-11156432, EBI-748380;
CC       Q9Y5P4-2; Q9UET6: FTSJ1; NbExp=3; IntAct=EBI-11156432, EBI-1055987;
CC       Q9Y5P4-2; Q9UPX6: MINAR1; NbExp=3; IntAct=EBI-11156432, EBI-11977115;
CC       Q9Y5P4-2; Q8IYS1: PM20D2; NbExp=3; IntAct=EBI-11156432, EBI-11339910;
CC       Q9Y5P4-2; Q96HR9-2: REEP6; NbExp=3; IntAct=EBI-11156432, EBI-14065960;
CC       Q9Y5P4-2; Q2TAY7: SMU1; NbExp=3; IntAct=EBI-11156432, EBI-298027;
CC       Q9Y5P4-2; P32856-2: STX2; NbExp=3; IntAct=EBI-11156432, EBI-11956649;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16895911,
CC       ECO:0000269|PubMed:18184806}. Golgi apparatus
CC       {ECO:0000269|PubMed:16895911, ECO:0000269|PubMed:18184806,
CC       ECO:0000269|PubMed:29858488}. Endoplasmic reticulum
CC       {ECO:0000269|PubMed:16895911, ECO:0000269|PubMed:18184806}.
CC       Note=Preferentially localized to the Golgi apparatus.
CC       {ECO:0000305|PubMed:16895911}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=CERTL {ECO:0000303|PubMed:14685229};
CC         IsoId=Q9Y5P4-1; Sequence=Displayed;
CC       Name=2; Synonyms=Delta26, GPBPD26, CERT {ECO:0000303|PubMed:14685229};
CC         IsoId=Q9Y5P4-2; Sequence=VSP_006276;
CC       Name=3;
CC         IsoId=Q9Y5P4-3; Sequence=VSP_041022;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DOMAIN: The START domain recognizes ceramides and diacylglycerol
CC       lipids, interacts with membranes, and mediates the intermembrane
CC       transfer of ceramides and diacylglycerol lipids.
CC       {ECO:0000269|PubMed:14685229}.
CC   -!- DOMAIN: The PH domain targets the Golgi apparatus.
CC       {ECO:0000269|PubMed:16895911}.
CC   -!- DOMAIN: The FFAT motif is required for interaction with VAPA, VAPB and
CC       MOSPD2. {ECO:0000269|PubMed:16895911, ECO:0000269|PubMed:29858488}.
CC   -!- PTM: Phosphorylation on Ser-132 decreases the affinity toward
CC       phosphatidylinositol 4-phosphate at Golgi membranes and reduces
CC       ceramide transfer activity. Inactivated by hyperphosphorylation of
CC       serine residues by CSNK1G2/CK1 that triggers dissociation from the
CC       Golgi complex, thus down-regulating ER-to-Golgi transport of ceramide
CC       and sphingomyelin synthesis. {ECO:0000269|PubMed:17591919,
CC       ECO:0000269|PubMed:19005213}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 34
CC       (MRD34) [MIM:616351]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:25356899, ECO:0000269|PubMed:25533962}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- CAUTION: Was originally reported to have a protein kinase activity and
CC       to phosphorylate on Ser and Thr residues the Goodpasture autoantigen
CC       (in vitro). {ECO:0000305|PubMed:10212244}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF136450; AAD30288.1; -; mRNA.
DR   EMBL; AF232930; AAG42046.1; -; mRNA.
DR   EMBL; AF232935; AAG42051.1; -; Genomic_DNA.
DR   EMBL; AY453385; AAR26717.1; -; mRNA.
DR   EMBL; AY453386; AAR26718.1; -; mRNA.
DR   EMBL; AK091851; BAC03762.1; -; mRNA.
DR   EMBL; AK096854; BAG53379.1; -; mRNA.
DR   EMBL; AK292087; BAF84776.1; -; mRNA.
DR   EMBL; AC008897; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC112183; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC116341; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471084; EAW95757.1; -; Genomic_DNA.
DR   EMBL; CH471084; EAW95760.1; -; Genomic_DNA.
DR   EMBL; BC000102; AAH00102.1; -; mRNA.
DR   EMBL; AB036934; BAB58974.1; -; Genomic_DNA.
DR   EMBL; AB036936; BAB58977.1; -; Genomic_DNA.
DR   CCDS; CCDS4028.1; -. [Q9Y5P4-1]
DR   CCDS; CCDS4029.1; -. [Q9Y5P4-2]
DR   CCDS; CCDS47235.1; -. [Q9Y5P4-3]
DR   RefSeq; NP_001123577.1; NM_001130105.1. [Q9Y5P4-3]
DR   RefSeq; NP_005704.1; NM_005713.2. [Q9Y5P4-1]
DR   RefSeq; NP_112729.1; NM_031361.2. [Q9Y5P4-2]
DR   RefSeq; XP_006714576.1; XM_006714513.2.
DR   RefSeq; XP_016864408.1; XM_017008919.1.
DR   PDB; 2E3M; X-ray; 2.20 A; A=347-624.
DR   PDB; 2E3N; X-ray; 1.40 A; A=347-624.
DR   PDB; 2E3O; X-ray; 1.55 A; A=347-624.
DR   PDB; 2E3P; X-ray; 1.40 A; A/B=347-624.
DR   PDB; 2E3Q; X-ray; 2.08 A; A=347-624.
DR   PDB; 2E3R; X-ray; 1.65 A; A/B=347-624.
DR   PDB; 2E3S; X-ray; 1.94 A; A=347-624.
DR   PDB; 2RSG; NMR; -; A=24-117.
DR   PDB; 2Z9Y; X-ray; 1.80 A; A=347-624.
DR   PDB; 2Z9Z; X-ray; 1.74 A; A=347-624.
DR   PDB; 3H3Q; X-ray; 2.00 A; A/B=347-624.
DR   PDB; 3H3R; X-ray; 1.85 A; A/B=347-624.
DR   PDB; 3H3S; X-ray; 1.66 A; A/B=347-624.
DR   PDB; 3H3T; X-ray; 2.40 A; A/B=347-624.
DR   PDB; 4HHV; X-ray; 1.75 A; A/B=20-121.
DR   PDB; 5JJD; X-ray; 2.40 A; A=20-122, B=385-624.
DR   PDB; 5ZYG; X-ray; 1.80 A; A=390-624.
DR   PDB; 5ZYH; X-ray; 1.95 A; A=390-624.
DR   PDB; 5ZYI; X-ray; 1.90 A; A=390-624.
DR   PDB; 5ZYJ; X-ray; 1.90 A; A=390-624.
DR   PDB; 5ZYK; X-ray; 1.55 A; A=390-624.
DR   PDB; 5ZYL; X-ray; 1.80 A; A=390-624.
DR   PDB; 5ZYM; X-ray; 1.90 A; A=390-624.
DR   PDB; 6IEZ; X-ray; 1.90 A; A=390-624.
DR   PDB; 6IF0; X-ray; 1.80 A; A=390-624.
DR   PDB; 6J0O; X-ray; 1.80 A; A=390-624.
DR   PDB; 6J81; X-ray; 1.80 A; A=390-624.
DR   PDBsum; 2E3M; -.
DR   PDBsum; 2E3N; -.
DR   PDBsum; 2E3O; -.
DR   PDBsum; 2E3P; -.
DR   PDBsum; 2E3Q; -.
DR   PDBsum; 2E3R; -.
DR   PDBsum; 2E3S; -.
DR   PDBsum; 2RSG; -.
DR   PDBsum; 2Z9Y; -.
DR   PDBsum; 2Z9Z; -.
DR   PDBsum; 3H3Q; -.
DR   PDBsum; 3H3R; -.
DR   PDBsum; 3H3S; -.
DR   PDBsum; 3H3T; -.
DR   PDBsum; 4HHV; -.
DR   PDBsum; 5JJD; -.
DR   PDBsum; 5ZYG; -.
DR   PDBsum; 5ZYH; -.
DR   PDBsum; 5ZYI; -.
DR   PDBsum; 5ZYJ; -.
DR   PDBsum; 5ZYK; -.
DR   PDBsum; 5ZYL; -.
DR   PDBsum; 5ZYM; -.
DR   PDBsum; 6IEZ; -.
DR   PDBsum; 6IF0; -.
DR   PDBsum; 6J0O; -.
DR   PDBsum; 6J81; -.
DR   AlphaFoldDB; Q9Y5P4; -.
DR   BMRB; Q9Y5P4; -.
DR   SMR; Q9Y5P4; -.
DR   BioGRID; 115396; 50.
DR   ELM; Q9Y5P4; -.
DR   IntAct; Q9Y5P4; 35.
DR   MINT; Q9Y5P4; -.
DR   STRING; 9606.ENSP00000369862; -.
DR   BindingDB; Q9Y5P4; -.
DR   ChEMBL; CHEMBL3399913; -.
DR   SwissLipids; SLP:000000407; -.
DR   iPTMnet; Q9Y5P4; -.
DR   PhosphoSitePlus; Q9Y5P4; -.
DR   BioMuta; COL4A3BP; -.
DR   DMDM; 20978413; -.
DR   EPD; Q9Y5P4; -.
DR   jPOST; Q9Y5P4; -.
DR   MassIVE; Q9Y5P4; -.
DR   MaxQB; Q9Y5P4; -.
DR   PaxDb; Q9Y5P4; -.
DR   PeptideAtlas; Q9Y5P4; -.
DR   PRIDE; Q9Y5P4; -.
DR   ProteomicsDB; 86463; -. [Q9Y5P4-1]
DR   ProteomicsDB; 86464; -. [Q9Y5P4-2]
DR   ProteomicsDB; 86465; -. [Q9Y5P4-3]
DR   Antibodypedia; 24390; 373 antibodies from 34 providers.
DR   DNASU; 10087; -.
DR   Ensembl; ENST00000261415.12; ENSP00000261415.8; ENSG00000113163.19. [Q9Y5P4-1]
DR   Ensembl; ENST00000405807.10; ENSP00000383996.4; ENSG00000113163.19. [Q9Y5P4-3]
DR   Ensembl; ENST00000643780.2; ENSP00000495760.1; ENSG00000113163.19. [Q9Y5P4-1]
DR   Ensembl; ENST00000644072.2; ENSP00000494110.2; ENSG00000113163.19. [Q9Y5P4-1]
DR   Ensembl; ENST00000644445.1; ENSP00000496243.1; ENSG00000113163.19. [Q9Y5P4-2]
DR   Ensembl; ENST00000645483.1; ENSP00000493563.1; ENSG00000113163.19. [Q9Y5P4-2]
DR   Ensembl; ENST00000646511.1; ENSP00000495446.1; ENSG00000113163.19. [Q9Y5P4-2]
DR   GeneID; 10087; -.
DR   KEGG; hsa:10087; -.
DR   MANE-Select; ENST00000643780.2; ENSP00000495760.1; NM_001379029.1; NP_001365958.1.
DR   UCSC; uc003kds.4; human. [Q9Y5P4-1]
DR   CTD; 10087; -.
DR   DisGeNET; 10087; -.
DR   GeneCards; CERT1; -.
DR   HGNC; HGNC:2205; CERT1.
DR   HPA; ENSG00000113163; Low tissue specificity.
DR   MalaCards; CERT1; -.
DR   MIM; 604677; gene.
DR   MIM; 616351; phenotype.
DR   neXtProt; NX_Q9Y5P4; -.
DR   OpenTargets; ENSG00000113163; -.
DR   PharmGKB; PA26720; -.
DR   VEuPathDB; HostDB:ENSG00000113163; -.
DR   eggNOG; KOG1739; Eukaryota.
DR   GeneTree; ENSGT00940000155123; -.
DR   HOGENOM; CLU_017289_0_0_1; -.
DR   InParanoid; Q9Y5P4; -.
DR   OMA; EDQSKKF; -.
DR   OrthoDB; 959972at2759; -.
DR   PhylomeDB; Q9Y5P4; -.
DR   TreeFam; TF106160; -.
DR   BRENDA; 2.7.11.9; 2681.
DR   PathwayCommons; Q9Y5P4; -.
DR   Reactome; R-HSA-1660661; Sphingolipid de novo biosynthesis. [Q9Y5P4-2]
DR   SignaLink; Q9Y5P4; -.
DR   SIGNOR; Q9Y5P4; -.
DR   BioGRID-ORCS; 10087; 31 hits in 1078 CRISPR screens.
DR   ChiTaRS; COL4A3BP; human.
DR   EvolutionaryTrace; Q9Y5P4; -.
DR   GeneWiki; COL4A3BP; -.
DR   GenomeRNAi; 10087; -.
DR   Pharos; Q9Y5P4; Tbio.
DR   PRO; PR:Q9Y5P4; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q9Y5P4; protein.
DR   Bgee; ENSG00000113163; Expressed in sperm and 212 other tissues.
DR   ExpressionAtlas; Q9Y5P4; baseline and differential.
DR   Genevisible; Q9Y5P4; HS.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:1902387; F:ceramide 1-phosphate binding; IBA:GO_Central.
DR   GO; GO:1902388; F:ceramide 1-phosphate transfer activity; IBA:GO_Central.
DR   GO; GO:0097001; F:ceramide binding; IDA:UniProtKB.
DR   GO; GO:0120017; F:ceramide transfer activity; IDA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IEA:Ensembl.
DR   GO; GO:0070273; F:phosphatidylinositol-4-phosphate binding; IDA:UniProtKB.
DR   GO; GO:0000902; P:cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0008283; P:cell population proliferation; IEA:Ensembl.
DR   GO; GO:0006672; P:ceramide metabolic process; IEA:Ensembl.
DR   GO; GO:0035627; P:ceramide transport; IBA:GO_Central.
DR   GO; GO:0007029; P:endoplasmic reticulum organization; IEA:Ensembl.
DR   GO; GO:0035621; P:ER to Golgi ceramide transport; IMP:UniProtKB.
DR   GO; GO:0003007; P:heart morphogenesis; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0120009; P:intermembrane lipid transfer; IBA:GO_Central.
DR   GO; GO:0120012; P:intermembrane sphingolipid transfer; IDA:UniProtKB.
DR   GO; GO:0055088; P:lipid homeostasis; IEA:Ensembl.
DR   GO; GO:0070584; P:mitochondrion morphogenesis; IEA:Ensembl.
DR   GO; GO:0006936; P:muscle contraction; IEA:Ensembl.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IEA:Ensembl.
DR   CDD; cd08872; START_STARD11-like; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.530.20; -; 1.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR041952; STARD11_START.
DR   InterPro; IPR023393; START-like_dom_sf.
DR   InterPro; IPR002913; START_lipid-bd_dom.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF01852; START; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00234; START; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS50848; START; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Coiled coil; Cytoplasm;
KW   Disease variant; Endoplasmic reticulum; Golgi apparatus;
KW   Intellectual disability; Lipid transport; Lipid-binding; Phosphoprotein;
KW   Reference proteome; Transport.
FT   CHAIN           1..624
FT                   /note="Ceramide transfer protein"
FT                   /id="PRO_0000220665"
FT   DOMAIN          23..117
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          389..618
FT                   /note="START"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00197"
FT   REGION          1..24
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          263..303
FT                   /evidence="ECO:0000255"
FT   MOTIF           321..327
FT                   /note="FFAT"
FT                   /evidence="ECO:0000269|PubMed:16895911,
FT                   ECO:0000269|PubMed:29858488"
FT   COMPBIAS        1..16
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         472
FT                   /ligand="an N-acylsphing-4-enine"
FT                   /ligand_id="ChEBI:CHEBI:52639"
FT                   /evidence="ECO:0000269|PubMed:18184806,
FT                   ECO:0000269|PubMed:20036255"
FT   BINDING         493
FT                   /ligand="an N-acylsphing-4-enine"
FT                   /ligand_id="ChEBI:CHEBI:52639"
FT                   /evidence="ECO:0000269|PubMed:18184806,
FT                   ECO:0000269|PubMed:20036255"
FT   BINDING         530
FT                   /ligand="an N-acylsphing-4-enine"
FT                   /ligand_id="ChEBI:CHEBI:52639"
FT                   /evidence="ECO:0000269|PubMed:18184806,
FT                   ECO:0000269|PubMed:20036255"
FT   BINDING         579
FT                   /ligand="an N-acylsphing-4-enine"
FT                   /ligand_id="ChEBI:CHEBI:52639"
FT                   /evidence="ECO:0000269|PubMed:18184806,
FT                   ECO:0000269|PubMed:20036255"
FT   MOD_RES         126
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         132
FT                   /note="Phosphoserine; by PKD"
FT                   /evidence="ECO:0000269|PubMed:17591919"
FT   MOD_RES         135
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9EQG9"
FT   MOD_RES         315
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983"
FT   MOD_RES         372
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         373
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1
FT                   /note="M -> MQHSCIPTPPSPFSAPPAFLPVVTRESRRGLSSGGSAGRNAGVTATA
FT                   AAADGWKGRLPSPLVLLPRSARCQARRRRGGRTSSLLLLPPTPERALFASPSPDPSPRG
FT                   LGASSGAAEGAGAGLLLGCRASM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041022"
FT   VAR_SEQ         371..396
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11007769,
FT                   ECO:0000303|PubMed:14685229, ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_006276"
FT   VARIANT         132
FT                   /note="S -> L (in MRD34; dbSNP:rs1064794019)"
FT                   /evidence="ECO:0000269|PubMed:25533962"
FT                   /id="VAR_073721"
FT   VARIANT         138
FT                   /note="S -> C (found in a patient with intellectual
FT                   disability)"
FT                   /evidence="ECO:0000269|PubMed:23033978"
FT                   /id="VAR_069403"
FT   VARIANT         243
FT                   /note="G -> R (in MRD34; associated with authism and
FT                   epilepsy)"
FT                   /evidence="ECO:0000269|PubMed:25356899"
FT                   /id="VAR_078652"
FT   VARIANT         599
FT                   /note="K -> R (in dbSNP:rs55882089)"
FT                   /id="VAR_061815"
FT   MUTAGEN         132
FT                   /note="S->A: Abolishes the phosphorylation. Strongly
FT                   reduces the interaction with phosphatidylinositol
FT                   4-phosphate. Increases the ceramide transfer activity."
FT                   /evidence="ECO:0000269|PubMed:17591919"
FT   MUTAGEN         324
FT                   /note="D->A: Impairs the endoplasmic reticulum-to-Golgi
FT                   ceramide trafficking and abolishes the interaction with
FT                   VAPA and MOSPD2."
FT                   /evidence="ECO:0000269|PubMed:16895911,
FT                   ECO:0000269|PubMed:29858488"
FT   MUTAGEN         472
FT                   /note="E->A: Reduces ceramide transfer."
FT                   /evidence="ECO:0000269|PubMed:18184806"
FT   MUTAGEN         493
FT                   /note="Q->A: No effect on ceramide transfer activity."
FT                   /evidence="ECO:0000269|PubMed:18184806"
FT   MUTAGEN         499
FT                   /note="W->A: Reduces affinity for membranes. Abolishes
FT                   ceramide transfer; when associated with A-588."
FT                   /evidence="ECO:0000269|PubMed:20036255"
FT   MUTAGEN         530
FT                   /note="N->A: Reduces ceramide transfer."
FT                   /evidence="ECO:0000269|PubMed:18184806"
FT   MUTAGEN         588
FT                   /note="W->A: Abolishes ceramide transfer; when associated
FT                   with A-499."
FT   STRAND          26..33
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   TURN            36..38
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   STRAND          40..48
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   STRAND          51..56
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   STRAND          58..62
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   STRAND          64..71
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   STRAND          75..78
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   STRAND          85..90
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   STRAND          93..98
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   HELIX           102..119
FT                   /evidence="ECO:0007829|PDB:4HHV"
FT   HELIX           397..407
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          413..415
FT                   /evidence="ECO:0007829|PDB:2E3M"
FT   STRAND          418..424
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          427..432
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          444..451
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   HELIX           455..463
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   HELIX           465..467
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   HELIX           468..471
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          474..485
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          488..495
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          499..502
FT                   /evidence="ECO:0007829|PDB:3H3S"
FT   STRAND          504..515
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          518..522
FT                   /evidence="ECO:0007829|PDB:2E3O"
FT   STRAND          525..532
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          542..546
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          548..559
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          563..565
FT                   /evidence="ECO:0007829|PDB:3H3S"
FT   HELIX           570..572
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          573..584
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   HELIX           591..617
FT                   /evidence="ECO:0007829|PDB:2E3N"
FT   STRAND          618..620
FT                   /evidence="ECO:0007829|PDB:2E3Q"
SQ   SEQUENCE   624 AA;  70835 MW;  A125162492AC5A0E CRC64;
     MSDNQSWNSS GSEEDPETES GPPVERCGVL SKWTNYIHGW QDRWVVLKNN ALSYYKSEDE
     TEYGCRGSIC LSKAVITPHD FDECRFDISV NDSVWYLRAQ DPDHRQQWID AIEQHKTESG
     YGSESSLRRH GSMVSLVSGA SGYSATSTSS FKKGHSLREK LAEMETFRDI LCRQVDTLQK
     YFDACADAVS KDELQRDKVV EDDEDDFPTT RSDGDFLHST NGNKEKLFPH VTPKGINGID
     FKGEAITFKA TTAGILATLS HCIELMVKRE DSWQKRLDKE TEKKRRTEEA YKNAMTELKK
     KSHFGGPDYE EGPNSLINEE EFFDAVEAAL DRQDKIEEQS QSEKVRLHWP TSLPSGDAFS
     SVGTHRFVQK PYSRSSSMSS IDLVSASDDV HRFSSQVEEM VQNHMTYSLQ DVGGDANWQL
     VVEEGEMKVY RREVEENGIV LDPLKATHAV KGVTGHEVCN YFWNVDVRND WETTIENFHV
     VETLADNAII IYQTHKRVWP ASQRDVLYLS VIRKIPALTE NDPETWIVCN FSVDHDSAPL
     NNRCVRAKIN VAMICQTLVS PPEGNQEISR DNILCKITYV ANVNPGGWAP ASVLRAVAKR
     EYPKFLKRFT SYVQEKTAGK PILF
//
